GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira for RLS

Nov 10, 2008 - GlaxoSmithKline and XenoPort, Inc. announced today that the NDA for Solzira (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) has been withdrawn.

The details can be read here.